The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells. by Yousefi, S. et al.
Br. J. Cancer (1991), 64, 243 246
© Macmillan Press Ltd.,
The paradoxical effects of somatostatin on the bioactivity and production
of cytotoxins derived from human peripheral blood mononuclear cells
S. Yousefi, N. Vaziri, G. Carandang, W. Le, R. Yamamoto, G. Granger, J. Ocariz &
T. Cesario
Department ofMedicine, University ofCalifornia Irvine, 101 The City Drive, Orange, California 92668, USA.
Summary Somatostatin (SMS), a naturally occurring peptide is known to inhibit the production of certain
protein molecules and to diminish the ability of peripheral blood mononuclear cells to proliferate. We tested
the effects of three forms of SMS on the bioactivity of both lymphotoxin (LT) and tumour necrosis factor
(TNF). We also tested the effects of these agents on production of cytotoxins by peripheral blood
mononuclear cells. We found the 28 amino acid form of SMS significantly enhanced the bioactivity of both
LT and TNF (10-9 M concentration) when tested in mouse L cells. The 14 amino acid form of SMS enhanced
LT (10-9 M concentration) activity but not TNF activity. The first 14 amino acid form of SMS-28 (amino
terminal) did not affect bioactivity of the cytotoxin. In contrast, the naturally occurring 14 amino acid form of
SMS (10-8 M concentration) significantly diminished production of cytotoxin by human peripheral blood
mononuclear cells. Cytotoxin produced by the latter was shown to be a combination of both LT and TNF.
Similarly after SMS exposure, the cytotoxin produced remained a mixture of LT and TNF in roughly similar
proportions. It thus appears that certain forms of SMS can enhance the bioactivity of cytotoxins, but at the
same time decrease the production of these cytotoxins.
Somatostatin (SMS) is a protein produced by cells of the
nervous system and gastrointestinal tract (Reichlin, 1983). It
is known to have many biological functions including the
ability to inhibit the secretion of various polypeptides such as
growth hormone (Brazeau et al., 1973; McCann et al., 1980)
insulin and glucagon (Reichlin, 1983). Because of its ability
to inhibit the secretion of various polypeptides, SMS analogs
have been used to control symptoms associated with tumours
that secrete biologically active peptides. Thus SMS analogs
have been used to treat gastrointestinal neoplasms that
induce diarrhea by producing peptides which stimulate the
flow of fluids into the lumen of the gastrointestinal tract
(Gordon et al., 1989; Schally, 1988). In addition to infuenc-
ing the endocrine system and the secretion of peptides by
neoplasms, SMS is known to affect the functions of the
immune system (Stanisz et al., 1986; Wagner et al., 1979;
Payan et al., 1984; Mascardo et al., 1984). Thus, it has been
reported that SMS can diminish the ability of mononuclear
cells to proliferate (Wagner et al., 1979; Payan et al., 1984;
Mascardo et al., 1984) and has been reported to inhibit the
production of lymphokines such as gamma interferon
(Yousefi et al., 1990) (IFN). The immune system itself
secretes a number of biologically active peptides including
cytokines. Since SMS does have a role in the treatment of
neoplastic diseases it seemed important to know if SMS can
adversely influence the secretion of cytotoxic cytokines used
by the immune system to influence tumour growth. We
therefore proceeded to determine the effects of SMS on the
production of cytotoxins by peripheral blood mononuclear
cells and simultaneously examined the influence of SMS on
the biological activities of these peptides. Different
biologically active forms of SMS including a 14 amino acid
and a 28 amino acid moiety (Reichlin, 1983) were included in
the tests since these varying moieties have somewhat different
biological roles (Gordon et al., 1989).
Materials and methods
Reagents
Phytohaemagglutinin-P (PHA) and concanavalin A (Con A)
were purchased from Difco Inc. (Detroit, Mich.).
The 14 amino acid moiety of somatostatin (SMS 14) (Gus-
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tavsson et al., 1978) the first 14 amino acid fragment (from
the amino terminal) of the 28 amino acid form of somato-
statin (SMS 28 [AA 1-14]) (Wunsch et al., 1981) and the
whole 28 amino acid of somatostatin moiety (SMS 28)
(Schally et al., 1980) were all obtained from Sigma Inc. (St
Louis, MO). Foetal bovine serum was purchased from Gibco
(Santa Clara, CA) and RPMI 1640 medium was obtained
from Irvine Scientific (Irvine, CA). Penicillin and strepto-
mycin were purchased from Pfizer Inc. (New York, NY).
Recombinant human tumour necrosis factor (rTNF) and
recombinant human lymphotoxins (rLT) were the gifts of
Genentech (South San Francisco, Calif.), 3H-thymidine was
purchased from ICN (Irvine, Calif.) and mitomycin C was
obtained from Sigma Inc. (St Louis, MO).
Polyclonal antisera to tumour necrosis factor and lympho-
toxin were provided by Dr Gale Granger, University ofCalif.
Irvine and prepared as previously reported (Lewis et al.,
1977).
Separation and mitogenic stimulation ofperipheral blood
mononuclear cells (PBMC)
Human peripheral blood mononuclear cells (PBMC) were
obtained as the buffy coat fraction from normal human
donors. PBMC were separated on Ficoll Hypaque gradients
(Boyum, 1968), (specific gravity of 1.077) washed and
adjusted to a final concentration of 2.5 x 106cells ml ' in
RPMI 1640 supplemented with 10% foetal bovine serum, 250
units of penicillin and 150fgml-' of streptomycin.
PBMC were stimulated with either 2.5 or 25 g ml1' of
PHA or 25jig ml-' of Con A. Incubation of the cells was
then carried out in 15 ml plastic centrifuge tubes in a 5%
CO2 incubator at 37°C for 3 days. At the end of that time,
the cells were removed by centrifugation, tested for viability
using trypan blue and exposed to 3H-thymidine as described
below. Biological assays with these cells were performed only
if the viability of the cells was 95% or greater. All super-
natants harvested from the PBMC after stimulation were
dialysed for 48 h against phosphate buffered saline with at
least five bath changes and frozen for subsequent cytotoxin
assay. The dialysis membrane used had a pore size that
excluded molecules greater than 5,000 Daltons and the
volume of the bath was 20 times greater than the volume of
the samples being dialysed. Dialysis was performed to
remove SMS. In those experiments where SMS was added to
the PBMC to study the effects on production of cytotoxin,
final dilutions of SMS were made just prior to addition to
the PBMC. Appropriate controls were performed for each
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test sample. Controls were simultaneously prepared and
treated in every way identically to the test samples save for
the absence of the SMS reagent.
Proliferative responses
Proliferative responses were determined by pulsing stimulated
and unstimulated PBMC at a cell concentration of 1 x 106
cells ml-' for 4 h in a CO2 incubator with 3H-thymidine
(0.51tCi/well) having a specific activity of 6.7 Ci nM- (ICN,
Irvine, CA). Aftr pulsing, the cells were harvested using a
multisample automatic cell harvester. The samples were
deposited on Filtermats (Skatron Inc., Lier, Norway) and the
precipitates washed extensively. The 3H-thymidine incorpora-
tion was measured using a liquid scintillation counter.
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Cytotoxin assays
Cytotoxin was assayed according to the methods reported
previously (Yamamoto et al., 1986). Briefly, confluent
monolayers of mitomycin C treated murine L929 cells in 96
well flat bottom microtiter plates were exposed to serial
2-fold dilutions of sample. After overnight incubation, plates
were stained with crystal violet, washed thoroughly with tap
water and dried completely. The bound dye was eluted by
95% ethanol and measured spectrophotometrically in a
Titertek Multiscan (Flow Laboratories, McLean, Va.) plate
reader. The cytotoxin titers were estimated by plotting the
absorbance as a function of the cytotoxin dilution and cal-
culating the end point as that last dilution where 50% of the
cells lysed (a 50% reduction in dye uptake). A standard
cytotoxin preparation provided by Dr Granger was employed
in every assay. The results are expressed in units ml-'. A unit
is the least amount of cytotoxin causing 50% destruction of
the target cells.
In those experiments where the effect of SMS on bio-
activity of rLT or rTNF was being tested, freshly diluted
SMS in the appropriate concentration (10-6 to lv " M) was
added with a microdropper to individual wells 'f the plate.
Immediately thereafter samples containing rLT or rTNF
were titrated on the plates. The assay was then carried out as
stated above. The titer of the cytotoxin as determined in the
presence of the SMS was compared to the titer in the absence
of the SMS.
Typing ofthe cytotoxins
Typing was accomplished by exposure of the L929 cells to
antisera specific to either human rTNF or human rLT.
Briefly, confluent monolayers of the L929 cells as above were
exposed 10 1l of polyclonal rabbit antiserum made to either
rTNF or rLT or, were exposed to an identical volume of
normal rabbit serum. Antisera were adjusted to neutralise at
least 200 units of activity prior to incubation and were shown
to be specific for either rLT or rTNF without cross neut-
ralisation at the dilutions used. After addition of the specific
antiserum or normal control serum, supernatants prepared
from the PBMC and shown to contain cytotoxins were added
to the wells and the cytotoxin assay as described above
completed. The per cent neutralisation (Lewis et al., 1977)
was calculated as
(1 -Titer in antiserum) x
100
Titer in normal serum
Statistical analysis
Statistical analysis was performed using the Student's paired
t-test.
Results
In order to understand the effect of a compound on a
biological substance it is necessary to examine the effects of
Figure 1 The effect of SMs on the bioactivity of recombinant
lymphotoxin (LT) in L929 cells. LII rLT without SMS, F
rLT with 10- M SMS, I rLT with 108 SMS, I rLT with
10-9 SMS, _ rLT with 10-10 SMS. The increase in titer of the
LT in the presence of SMS 28 at the 108 and 10-9 M concentra-
tion is significantly greater than the titer in the absence of SMS
(P <.05). Similarly the increase in the titer of LT in the presence
of SMS 14 at a concentration of 10-9 M is significant (P <.01).
Each bar represents a mean of 12 experiments.
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Figure 2 The effect of SMS on the bioactivity of recombinant
tumour necrosis factor. LII recombinant rTNF without SMS,
M recombinant TNF with SMS 10-7M. 10 rTNF with
10-8M SMS, X rTNF with 10-9M SMS, - rTNF with
10-1°M SMS.
The increase in titer of TNF in the presence of 10-9 M SMS 28
is significant (P <.05). Each bar is derived from a mean of twelve
experiments. The error bar for SMS 28 at the 10-8 M concentra-
tion ends exactly on the line at the edge of the figure.
the compound on both the production and the bioactivity of
the substance. Thus to understand the effects of SMS we
investigated the influence of SMS on the cytotoxicity of both
rLT and rTNF. Figure 1 demonstrates the effect of the three
forms of SMS on the bioactivity of recombinant lymphotoxin
(LT). It can be seen that the 28 amino acid form of SMS
(SMS 28) significantly enhanced the bioactivity of LT. The
greatest increase was seen at the 10-8 M concentration where
the presence of the peptide enhanced LT activity 4-fold. At
this concentration enhanced activity was seen in 11 of the 12
experiments. At l0-9 M, SMS still enhanced activity. In addi-
tion, two forms of the 14 amino acid SMS moiety were
tested. These represent the naturally occurring tetradecapep-
tide and the first 14 amino acids from the amino terminal of
the 28 amino acid SMS moiety. The latter was included as a
control. The natural 14 amino acid form of SMS 14 was
shown (Figure 1) to enhance LT activity by a factor of four
with peak activity at the l0-' M concentration. This observed
increase in activity was again seen in all of the 12
experiments. In contrast, SMS 28 (AA 1-14) had no effect on
LT activity.
Control experiments with SMS of all three types demon-
strated that the agent itself had no effect on the L929 cellsSOMATOSTATIN AND CYTOTOXINS 245
(when exposed to the cells for the standard 24 h incubation
period of the assay) as demonstrated either by light micro-
scopy or by the ability of the cells to stain with crystal violet.
Thus the SMS was not toxic to the cells.
In Figure 2 we have illustrated the results of SMS on the
bioactivity of TNF. It can be seen that SMS 28 enhanced
TNF activity with significance achieved at the 10' M con-
centration. This increase in activity was seen in 11 of the 12
experiments run. Neither SMS 14 or SMS 28 (AA 1-14)
affected the titer of the TNF to a statistically significant
degree.
In Figure 3, we have shown the effect of SMS on the
production of cytotoxins by PBMC. When PBMC are treated
with SMS alone, no cytokines were detected in the super-
natants from the treated PBMC. When similar cells were
treated for 24 h with SMS 14, incubated for 24 h and then
washed free of this tetradecapeptide and subsequently
stimulated with 25tggml-1 of PHA for 72h, the titer of
cytotoxins detected in the supernatant was the same as in
supernatants taken from control PBMC induced with PHA
but not exposed to SMS 14. Thus preincubation with re-
moval of the SMS did not affect the ability of the cells to
produce cytotoxin (data not shown). In contrast when SMS
was added with tihe inducer (Figure 3), an adverse effect was
appreciated on the titer of these cytotoxins induced in the
presence of SMS as compared to the titer induced by PHA in
the absence of SMS. Using the naturally occurring 14 amino
acid moiety, a significant reduction in cytotoxin activity as
compared to controls was appreciated at the 10' M and
10-8 M SMS concentrations. At both higher and lower dilu-
tions of the SMS no effects were appreciated. Similar results
were obtained when Con A was used as the inducer. In
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Figure 3 The effect of SMS 14 on the production of cytotoxins
induced in PBMC. The first two bars indicate no cytotoxin was
induced in the cells alone or in the presence of SMS 14. LII
cytotoxin produced by PHA with 106 M SMS. EI cytotoxin
produced by PHA + 10- M SMS, m cytotoxin produced by
PHA + 10-8 M SMS. m cytotoxin produced by PHA with
10-9M SMS. _ Cytotoxin produced by PHA with 10 '0M
SMS. PHA alone 1g3. The reduction in titer in the presence of
10-7 M and 10-8 M SMS is significant (P <.05). Each bar is
derived from a mean of 24 experiments performed on cells form
12 separate donors.
virtually every test run with the naturally occurring form of
SMS, the yield of cytotoxin was reduced. The 28 amino acid
moiety had no effects on production of these cytokines (data
not shown) including under those circumstances when the
PHA concentration was reduced to suboptimal levels (i.e.,
0.25 and 2.5ftgmml-').
When the cytotoxin produced by PBMC was neutralised
using specific antisera, we found the cytotoxic activity
induced by PHA was neutralised by antitoxin specific for
both TNF and LT. The same was true of the cytotoxin
induced by PHA in the presence of 10-8 M SMS (Table I).
In contrast to previous studies (Stanisz et al., 1986;
Wagner et al., 1979; Payan et al., 1984; Mascardo, 1984) we
could not demonstrate a reduction in the proliferative re-
sponses over the concentrations demonstrated here.
Discussion
Somatostatin, a neuropeptide, has been reported to inhibit T
cell proliferation and influence other immune functions
(Stanisz et al., 1986; Wagner et al., 1979; Payan et al., 1984;
Mascardo et al., 1984; Yousefi, et al., 1990). In the past, we
have reported that SMS of both 14 and 28 amino acid
species will decrease the production of human interferon
gamma but not interferon alpha (Yousefi et al., 1990). In this
report we have demonstrated the paradoxical effects of SMS
on cytotoxins produced by the immune system.
It is of interest that recombinant SMS in both 14 and 28
amino acid forms enhanced activity of LT on L929 cells. This
approximately 3-fold enhancement occurred at concentra-
tions slightly above those encountered physiologically
(Labhart, 1986) but could approximate the ranges of concen-
trations encountered in the therapy of neoplastic diseases
with SMS analogs (Kutz et al., 1986). It is of interest that
cytotoxic activity is statistically significantly increased over a
very narrow range of concentrations not including the
highest concc;. .. .ions tested. This same phenomena has been
observed elsewhere (Payan et al., 1984; Pawlikowski et al.,
1985).
In our data, enhancement of bioactivity by naturally
occurring forms of SMS was consistently observed with both
LT and TNF at the 10-9 M concentrations except when
studying SMS 14 and TNF. SMS in all forms tested was not
toxic to the cells in the absence of cytotoxins. We suggest
SMS could promote injury caused by the cytotoxins by
inhibiting the synthesis of enzymes used to repair damage
induced by LT and TNF.
It is not surprising that SMS 28 (AA 1-14) had no effect
on LT activity. The last 14 amino acid fragment of SMS 28,
i.e. the carboxyl terminal, bears strong resemblance to the
naturally occurring 14 amino acid moiety. The last 11 amino
acids from the carboxyl terminal are identical between the
two molecules and may represent the active component in its
effects on the immune system. Similar effects were seen on
gamma interferon production (Yousefi et al., 1990).
SMS 28 also significantly enhanced TNF activity at the
10-9 concentration. The 14 amino acid form did increase
activity, but not to a statistically significant degree. That
differences exist in the effect of LT and TNF in the presence
of SMS is not surprising because recent information has
Table I Typing of the peripheral blood mononuclear cell derived cytotoxin using specific
antisera
Percent Percent Percent
Titer neutralisation neutralisation neutralisation
before with with with both
Treatment treatment* anti-LT serum anti-TNF serum antisera
Recombinant LT 100 ± 23 100 0
Recombinant TNF 205 ± 15 0 100
PBMC + PHA 557 123 80 72 100
PBMC + PHA 183 27 67 70 100
+ SMS (10-8 M)
*Mean of three experiments.246 S. YOUSEFI et al.
suggested that the effects of these two cytokines may differ in
various cell types (Browning & Ribolini, 1989).
Since SMS does inhibit the secretion of other peptides
(Brazeau et al., 1973; McCann et al., 1980) including those of
the immune system (Yousefi et al., 1990), it might be
anticipated that it would also decrease the secretion of
cytotoxic cytokines. This inhibition occurs in ranges that are
above those encountered in the circulation (Labhart, 1986).
However, such levels of SMS could possibly be found in
areas proximate to the cells secreting SMS (paracrine effect).
Further, as cells of the immune system have been reported to
produce SMS (Goetzl et al., 1985), an autocrine effect might
be possible.
Results presented here suggest that SMS 14 is responsible
for inhibition of the production of cytotoxic cytokines but
that SMS 28 is not. This is again in keeping with the
differing effects of these SMS moieties (Gordon et al., 1989).
Our data suggest that SMS affected both TNF and LT
synthesis since neutralisation experiments with specific
antisera showed cytotoxin produced in the presence of SMS
was partially neutralised by both anti-TNF and anti-LT sera.
This is identical to results on the cytotoxin produced by PHA
without SMS. The production of TNF and LT are regulated
differently (Centuri et al., 1987), and these two cytokines are
produced by dissimilar cell types (Goeddel et al., 1986; Paul
& Ruddle, 1988), thus it is possible an agent could affect the
production of one cytotoxin, but not the other. The
mechanism of the inhibition in production ofcytokines could
possibly relate to the fact SMS may influence membrane
permeability to calcium (Pace & Tarvin, 1981) which is
important in the secretion of other cytokines (Cesario et al.,
1988). Since SMS does affect bioactivity, we had exhaustively
dialysed (with five bath changes) supernatants to remove
SMS. Furthermore a pore size was selected in the dialysis
membrane that easily allows SMS to pass, but does not affect
passage of the cytokines.
We did not find an effect of SMS on proliferation in
contrast to the work of others (Payan et al., 1984; Mascardo
et al., 1984; Pawlikowski et al., 1985). This is our case may
relate to the shorter (4 h) exposure period for thymidine
uptake we have used for convenience since our major thrust
is cytokine production. We have reported in earlier studies
that proliferation was decreased using octreotide (Yousefi et
al., 1990); however, previous work with gamma interferon
has established that secretion of cytokines can be dissociated
from the proliferative response (Berenbaum et al., 1975).
Our findings may have some clinical relevance. The
significant enhancement of LT and TNF found here in vitro
with murine cells if encountered in the body and against
other cell types suggests SMS could influence tumour growth
by potentiating the cytotoxic effects of LT and TNF as well.
This hypothesis will remain for on-going investigations to
verify.
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